Orion Biotechnology Canada Ltd, a drug discovery company focused on G-protein-coupled receptors, and Peptilogics, a biotechnology company designing a peptide therapy that combines computers and biology to improve the therapeutic landscape for patients with life-threatening diseases. , announced today who has entered research and development collaboration to use AI for drug discovery against a non-drug GPCR target.
The collaboration combines the capabilities of Peptilogics’ AI platform (NautilusTM) with Orion Biotechnology’s drug discovery platform. The companies will use expertise in peptide design and engineering to guide drug discovery against a non-pharmacological peptidergic GPCR linked to common and life-threatening diseases.
Peptilogics’ Nautilus™ platform enables the predictive design of peptides in silico across multiple targets to effectively access new chemical functional spaces and personalized therapies. In addition, the Peptilogics supercomputer accelerates model development, prediction, and evaluation of peptide sequences to produce higher quality results with a greater likelihood of success. In synergy, the Orion Biotechnology platform explores the space in a receptor-ligand fashion using proprietary multiplex synthesis technology to generate precision-engineered peptides with enhanced power and personalized signal activity. Orion’s platform generates AI-powered lead optimization data matrices, providing one of the fastest drug discovery and development solutions to address peptidergic GPCRs.
With the announcement of this collaboration, Dr. Oliver Hartley, Vice President of Drug Discovery at Orion Biotechnology, said: “We are excited to partner with Peptilogics to push the boundaries of receptor pharmacology and AI to accelerate innovation and improve patient outcomes. An AI-driven paradigm shift is taking place and Orion is pleased to be at the forefront of applying AI to the highly valuable space around the optimal fit of the GPCR between the Orion platform and unique knowledge of receptor-ligand interactions with Peptilogics’ machine learning models, we will position ourselves to advance AI to realize reality discovery – guided GPCR medicine.
Information about Orion Biotechnology
Orion Biotechnology Canada Ltd. unlocks the therapeutic potential of previously uncontrollable G protein-coupled receptors (GPCRs). Orion’s world-renowned experts in GPCR pharmacology and peptide/protein engineering use Orion’s drug discovery platform to quickly and efficiently develop a diverse portfolio of targeted therapy candidates with precise GPCR for the treatment of cancer and other serious illnesses.